Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yueping Li

Showing results (131-140 of 134) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 134 results.
Nature Communications|September 6, 2022
Publisher Correction: Clinical characteristics and immune profile alterations in vaccinated individuals with breakthrough Delta SARS-CoV-2 infectionsQinghong Fan, Jingrong Shi, Yanhong Yang, et al.
Eclinicalmedicine|January 8, 2024
Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trialYangqing Zhan, Zhengshi Lin, Jingyi Liang, et al.
Signal Transduction and Targeted Therapy|December 17, 2021
COVID-19 induces new-onset insulin resistance and lipid metabolic dysregulation via regulation of secreted metabolic factorsXi He, Chenshu Liu, Jiangyun Peng, et al.
Cell Metabolism|February 24, 2024
Gut microbial co-metabolite 2-methylbutyrylcarnitine exacerbates thrombosis via binding to and activating integrin α2β1Kan Huang, Zilun Li, Xi He, et al.
Pageof 14

Showing results (131-140 of 134) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 134 results.
Nature Communications|September 6, 2022
Publisher Correction: Clinical characteristics and immune profile alterations in vaccinated individuals with breakthrough Delta SARS-CoV-2 infectionsQinghong Fan, Jingrong Shi, Yanhong Yang, et al.
Eclinicalmedicine|January 8, 2024
Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trialYangqing Zhan, Zhengshi Lin, Jingyi Liang, et al.
Signal Transduction and Targeted Therapy|December 17, 2021
COVID-19 induces new-onset insulin resistance and lipid metabolic dysregulation via regulation of secreted metabolic factorsXi He, Chenshu Liu, Jiangyun Peng, et al.
Cell Metabolism|February 24, 2024
Gut microbial co-metabolite 2-methylbutyrylcarnitine exacerbates thrombosis via binding to and activating integrin α2β1Kan Huang, Zilun Li, Xi He, et al.
Pageof 14